供体糖尿病与1年角膜后弹力层内皮角膜移植术成功率:一项随机临床试验
这项多中心、双盲、随机临床试验纳入1097例受试者(1421只研究眼),比较使用无糖尿病与有糖尿病供体角膜行角膜后弹力层内皮角膜移植术(DMEK)的1年移植成功率。无糖尿病供体组1年累积成功率为96.3%,有糖尿病供体组为97.1%,两组差异无统计学显著(P=0.63)。结论认为,无论供体糖尿病状态如何,成功制备组织的DMEK 1年成功率均很高,支持不限制使用糖尿病供体组织行DMEK。
要点
- 有糖尿病供体组1年累积移植成功率为97.1%,无糖尿病供体组为96.3%,差异无统计学显著(P=0.63)。
- 轻度供体糖尿病亚组1年累积成功率为96.5%,中重度亚组为97.3%。
- 两组均无因移植排斥导致的失败。
核心结论
- 无论供体糖尿病状态如何,成功制备组织的DMEK 1年成功率均很高,支持不限制使用糖尿病供体组织行DMEK。
研究设计与样本
- 多中心、双盲、随机临床试验,2022年2月至2025年7月在美国28个临床中心(46名外科医生)开展,供体角膜由13家眼库提供。
- 纳入接受低至中等风险DMEK的个体(95%为Fuchs内皮性角膜营养不良),采用最小化程序(类似于随机化)按约2:1分配至无糖尿病供体组和有糖尿病供体组。
- 共纳入1097例受试者(1421只研究眼),中位年龄71岁(IQR 66-76),女性631例(57.5%)。
主要发现
- 无糖尿病供体组912只研究眼(64.2%)1年累积移植成功率为96.3%(95%CI 95.0%-97.5%),有糖尿病供体组509只研究眼(35.8%)为97.1%(95%CI 95.5%-98.4%),组间差异0.7个百分点(95%CI -1.2至2.6;P=0.63)。
- 轻度供体糖尿病严重程度亚组(n=173)1年累积成功率为96.5%(95%CI 93.6%-98.9%),中重度亚组(n=336)为97.3%(95%CI 95.4%-98.8%)。
- 无糖尿病供体组原发性供体失败、与手术并发症相关的早期失败和后续失败的发生率分别为2.5%(23/912)、0.7%(6/912)和0.3%(3/912);有糖尿病供体组分别为2.6%(13/509)、0.4%(2/509)和0%。
- 两组均无因移植排斥导致的失败。
临床怎么用
- 作者认为,这些结果(辅以另行报告的1年后内皮细胞丢失和角膜形态测量未受供体糖尿病状态影响)强烈支持不限制使用糖尿病供体组织行DMEK。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: If the success of Descemet membrane endothelial keratoplasty (DMEK) is not affected by whether the donor has diabetes, then the donor pool should expand. OBJECTIVE: To determine whether the 1-year DMEK success rate is affected by the presence of diabetes in the donor. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2025 at 28 clinical sites (46 surgeons), with donor corneas provided by 13 eye banks in the US. Included in the study were individuals undergoing low to moderate risk DMEK (95% for Fuchs endothelial corneal dystrophy). Study data were analyzed from April to September 2025. INTERVENTION: DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure (comparable with randomization) to achieve an approximate 2:1 distribution, respectively. MAIN OUTCOMES AND MEASURES: Graft success at 1 year. RESULTS: A total of 1097 individuals (1421 study eyes; median [IQR] age, 71 [66-76] years; 631 female [57.5%]) were included in the study. The 1-year cumulative probability of graft success was 96.3% (95% CI, 95.0%-97.5%) among 912 study eyes (64.2%) receiving tissue from donors without diabetes and 97.1% (95% CI, 95.5%-98.4%) among 509 study eyes (35.8%) receiving tissue from donors with diabetes (difference between groups = 0.7 percentage points; 95% CI, -1.2 to 2.6; P = .63). The 1-year cumulative probability of graft success was 96.5% (95% CI, 93.6%-98.9%) in the mild donor diabetes severity subgroup (n = 173) and 97.3% (95% CI, 95.4%-98.8%) in the moderate to severe donor diabetes severity subgroup (n = 336), using a diabetes severity rating scale based on medical history. The rates of primary donor failure, early failure related to surgical complications, and subsequent failure were as follows: 2.5% (23 of 912), 0.7% (6 of 912), and 0.3% (3 of 912), respectively, in recipients of tissue from a donor without diabetes, and 2.6% (13 of 509), 0.4% (2 of 509), and 0%, respectively, among recipients of tissue from a donor with diabetes. There were no failures due to graft rejection. CONCLUSIONS AND RELEVANCE: The 1-year success rate in eyes undergoing DMEK with successfully prepared tissue was very high regardless of donor diabetes status. These results, supported by the separately reported finding that endothelial cell loss and cornea morphometry after 1 year were not affected by donor diabetes status, provide strong support for having no restrictions on the use of tissue from donors with diabetes for DMEK. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05134480.
引用
- Price FW, Szczotka-Flynn LB, Price MO, et al. Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate: A Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 41105094. doi:10.1001/jamaophthalmol.2025.4253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。